In a report released today, Brandon Folkes from Cantor Fitzgerald maintained a Buy rating on BioDelivery (BDSI), with a price target of $5. The company’s shares closed yesterday at $4.07, close to its 52-week high of $4.38.
Folkes wrote:
“We view BDSI as a Belbuca execution story, and, based on Symphony script data, the company is exceeding its execution goals as well as our expectations. Execution, as well as increased access for Belbuca going into 2019 have increased our conviction that solid execution in 2019 and beyond is likely to continue, which should drive upward earnings revisions and further upside in BDSI stock. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $5.00.”
According to TipRanks.com, Folkes has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.8% and a 24.3% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.
BioDelivery has an analyst consensus of Strong Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.38 and a one-year low of $1.70. Currently, BioDelivery has an average volume of 640K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction.
